Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates

Destiny Pharma
Posted on: 20 Jul 18

Research to investigate potential antimicrobial candidates against biofilms



Brighton, United Kingdom – 17 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces it has signed a three-year research collaboration agreement with Aston University. The research is intended to examine novel compounds from the Company’s XF-platform and assess their potential to prevent, control and eradicate dangerous bacteria and biofilms.


Serious infections are sometimes caused and exacerbated by biofilms where bacteria can hide and be protected from traditional anti-infective agents. XF compounds have already shown efficacy in biofilm models and this research project will explore that further and look at the mechanisms of action. The collaboration with Aston University will also look at other potential uses of the XF platform in the prevention and treatment of serious, drug resistant infections. Aston University’s Department of Life and Health Sciences has established expertise in in vitro bacterial biofilm models that will be utilised in the collaboration. Financial terms of the collaboration have not been disclosed.


Tony Worthington, Reader in Clinical Microbiology at Aston University, commented:

“The XF series of compounds have distinctive properties that could provide important advances in the treatment of biofilm-related infections. We are delighted to work with Destiny Pharma on the evaluation of these compounds.”


Neil Clark, Chief Executive Officer of Destiny Pharma, added:

“We are excited to collaborate with the expert team at Aston University and look forward to exploring the further potential of our XF-platform, especially in the treatment of infections involving biofilms. Biofilms represent a significant barrier to antimicrobial treatment and this collaboration, which is in line with our stated strategy, may identify additional clinical candidates that are safe, effective and with a significantly reduced level of antimicrobial resistance.”


Biofilms are an increasing problem that are poorly treated by current drugs as they act as a protective barrier for bacteria and have been traditionally associated with indwelling medical devices (for example, heart valves and joint replacements) and invasive medical devices (for example, catheters and endoscopes). It is now acknowledged that biofilms have a major involvement in bacterial vaginosis, urinary tract infections, middle-ear infections, gingivitis, corneal infections and more lethal diseases such as endocarditis and cystic fibrosis. More recently it has been noted that bacterial biofilms may impair cutaneous wound healing and reduce topical antibacterial efficiency in healing or treating infected skin wounds, including burns and leg ulcers.


For further information, please contact:


Destiny Pharma plc

Neil Clark, CEO

Simon Sacerdoti, CFO

+44 (0)1273 704 440


Aston University

Press and Public Relations

+44 (0)121 204 4592


FTI Consulting

Simon Conway / Victoria Foster Mitchell

+44 (0) 20 3727 1000


Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000


finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500

Editor's Details

Mike Wood

Last updated on: 20/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.